Effect of dietary flavonoids on pathways involved in drug metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 1, 2008, Pages 17-35

  Cermak, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Drug transporters; Flavonoids; Phase I metabolism; Phase II metabolism

Indexed keywords

ACACETIN; AGLYCONE; ALPHA NAPHTHOFLAVONE; APIGENIN; BENZODIAZEPINE; CAFFEINE; CHALCONE DERIVATIVE; CHRYSIN; CYTOCHROME P450; DIOSMETIN; DRUG CARRIER; FLAVANONE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; FLAVONOLIGNAN; ISOFLAVONE DERIVATIVE; ISORHAMNETIN; KAEMPFEROL; MIDAZOLAM; POLYPHENOL; PROPRANOLOL; QUERCETIN; SILIBININ; THEOPHYLLINE; TOPOTECAN; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE; WARFARIN;

DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG USE; ENZYME INHIBITION; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; LEGAL ASPECT; NONHUMAN; PREDICTION; REVIEW;

ANIMALS; CARRIER PROTEINS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FLAVONOIDS; FOOD-DRUG INTERACTIONS; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 39049146064     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.1.17     Document Type: Review

References (153)

1. Kühnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976;24:117-91
2. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56(11):317-33
3. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000;55(6):481-504
4. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004;79(5):727-47
5. Hertog MGL, Hollman PCH, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993;20(1):21-9
6. De Vries JHM, Janssen PL, Hollman PCH, Van Staveren WA, Katan MB. Consumption of quercetin and kaempferol in free-living subjects eating a variety of diets. Cancer Lett 1997;114(1-2):141-4
7. Radtke J, Linseisen J, Wolfram G. Fasting plasma concentrations of selected flavonoids as markers of their ordinary dietary intake. Eur J Nutr 2002;41(5):203-9
8. Sampson L, Rimm EB, Hollman PCH, De Vries JHM, Katan MB, Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 2003;102(10):1414-20
9. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52(4):673-751
10. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002;96(2-3):67-202
11. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993;341(8843):454-7
12. Erdman JW, Balentine D, Arab L, et al. Flavonoids and heart health. Proceedings of the ILSI North American flavonoids workshop, May 31-June 1, 2005, Washington, DC. J Nutr 2007;137(3):S718-37
13. Graf BA, Milbury PE, Blumberg JB. Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food 2005;8(3):281-90
14. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002;136(1):42-53
15. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001;135(4):262-68
16. VitaNet® LLC Health Foods Website. Available at: URL: vitanetonline.com/description/SN1690/vitamins/ Activated-Quercetin-Capsule/ [accessed 30 September 2007]
17. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287(3):337-44
18. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs 2001;61(15):2163-75
19. Cheng ZQ, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999;27(10):1165-70
20. Boersma MG, van der Woude H, Bogaards J, et al. Regioselectivity of Phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 2002;15(5):662-70
21. Otake Y, Hsieh F, Walle T. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab Dispos 2002;30(5):576-81
22. O'Leary KA, Day AJ, Needs PW, Mellon FA, O'Brien NM, Williamson G. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human β-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 2003;65(3):479-91
23. De Santi C, Pietrabissa A, Mosca F, Pacifici GM. Methylation of quercetin and fisetin, flavonoids widely distributed in edible vegetables, fruits and wine, by human liver. Int J Clin Pharmacol Ther 2002;40(5):207-12
24. Gradolatto A, Canivenc-Lavier MC, Basly JP, Siess MH, Teyssier C. Metabolism of apigenin by rat liver Phase I and Phase II enzymes and by isolated perfused rat liver. Drug Metab Dispos 2004;32(1):58-65
25. Galijatovic A, Otake Y, Walle UK, Walle T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 1999;29(12):1241-56
26. Zhang L, Lin G, Zuo Z. Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein. Pharm Res 2007;24(1):81-9
27. Crespy V, Morand C, Manach C, Besson C, Demigné C, Rémésy C. Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol 1999;277(1):G120-6
28. Petri N, Tannergren C, Holst B, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of Phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003;31(6):805-13
29. Cermak R, Wolffram S. The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Curr Drug Metab 2006;7(7):729-44
30. Blaut M, Schoefer L, Braune A. Transformation of flavonoids by intestinal microorganisms. Int J Vitam Nutr Res 2003;73(2):79-87
31. Aura AM, O'Leary KA, Williamson G, et al. Quercetin derivatives are deconjugated and converted to hydroxyphenylacetic acids but not methylated by human fecal flora in vitro. J Agric Food Chem 2002;50(6):1725-30
32. Cermak R, Breves G, Lüpke M, Wolffram S. In vitro degradation of the flavonol quercetin and of quercetin glycosides in the porcine hindgut. Arch Anim Nutr 2006;60(2):180-9
33. Walle UK, Galijatovic A, Walle T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 1999;58(3):431-8
34. Sesink ALA, Arts ICW, De Boer VCJ, et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 2005;67(6):1999-2006
35. Hu M, Chen J, Lin H. Metabolism of flavonoids via enteric recycling. Mechanistic studies of disposition of apigenein in the Caco-2 cell culture model. J Pharmacol Exp Ther 2003;307(1):314-21
36. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS. Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun 2003;310(1):222-7
37. Williamson G, Aeberli I, Miguet L, et al. Interaction of potential isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2). Drug Metab Dispos 2007;35(8):1262-8
38. Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 2005;57(6):751-8
39. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996;24(5):521-33
40. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2(2):171-82
41. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein. Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13(3):129-34
42. Wang YH, Chao PDL, Hsiu SL, Wen KC, Hou YC. Lethal quercetin-digoxin interaction in pigs. Life Sci 2004;74(10):1191-7
43. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81(2):298-304
44. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34(1&2):83-448
45. Obermeier MT, White RE, Yang CS. Effects of bioflavonoids on hepatic P450 activities. Xenobiotica 1995;25(6):575-84
46. Doostdar H, Burke MD, Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000;144(1-3):31-8
47. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993;35(4):431-6
48. Tsyrlov IB, Mikhailenko VM, Gelboin HV. Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim Biophys Acta 1994;1205(2):325-35
49. Zhai SP, Dai R, Wei XX, Friedman FK, Vestal RE. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci 1998;63(8):PL119-23
50. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294(1):88-95
51. Von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004;56(8):1039-44
52. Chang TKH, Chen J, Yeung EYH. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 2006;213(1):18-26
53. Henderson MC, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupus. Xenobiotica 2000;30(3):235-51
54. Canivenc-Lavier MC, Vernevaut MF, Totis M, Siess MH, Magdalou J, Suschetet M. Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Toxicology 1996;114(1):19-27
55. Canivenc-Lavier MC, Bentejac M, Miller ML, et al. Differential effects of nonhydroxylated flavonoids as inducers of cytochrome P450 1A and 2B isozymes in rat liver. Toxicol Appl Pharmacol 1996;136(2):348-53
56. Ueng YF, Chang YL, Oda Y, et al. In vitro and in vivo effects of naringin on cytochrome P450-dependent monooxygenase in mouse liver. Life Sci 1999;65(24):2591-602
57. Ueng YF, Shyu CC, Lin YL, Park SS, Liao JF, Chen CF. Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice. Life Sci 2000;67(18):2189-200
58. Smith TJ, Guo Z, Guengerich FP, Yang CS. Metabolism of 4-(methynitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis 1996;17(4):809-13
59. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006;20(2):187-210
60. Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002;30(6):709-15
61. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54(21):5543-6
62. Václavíková R, Horský ŠImek P, Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmied Arch Pharmacol 2003;368(3):200-9
63. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32(6):587-94
64. Jang SI, Kim HJ, Hwang KM, et al. Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. Immunopharmacol Immunotoxicol 2003;25(4):585-94
65. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992;261(3):1195-9
66. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17β-estradiol. Eur J Drug Metab Pharmacokinet 1995;20(3):219-24
67. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004;11(4):262-77
68. Alvarez-González I, Madrigal-Bujaidar E, Dorado V, Espinosa-Aguirre JJ. Inhibitory effect of naringin on the micronuclei induced by ifosfamide in mouse, and evaluation of its modulatory effect on the Cyp3a subfamily. Mutat Res 2001;480-481:171-8
69. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28(11):1270-3
70. Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106(1):97-132
71. Wang LQ, James MO. Inhibition of sulfotransferase by xenobiotics. Curr Drug Metab 2006;7(1):83-104
72. Bosch TM, Meijerman I, Beijnen JH, Schellens JHM. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45(3):253-85
73. Galijatovic A, Otake Y, Walle UK, Walle T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells - potential role in carcinogen bioinactiviation. Pharm Res 2001;18(3):374-9
74. Walle T, Otake Y, Galijatovic A, Ritter JK, Walle UK. Induction of UDP-glucuronosyltransferase UGT 1A1 by the flavonoid chrysin in the human hepatoma cell line Hep G2. Drug Metab Dispos 2000;28(9):1077-82
75. Chlouchi A, Girard C, Bonet A, et al. Effect of chrysin and natural coumarins on UGT1A1 and 1A6 activities in rat and human hepatocytes in primary culture. Planta Med 2007;73(8):742-7
76. Walle UK, Walle T. Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids - structural requirements. Drug Metab Dispos 2002;30(5):564-9
77. Sugatani J, Yamakawa K, Tonda E, et al. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 2004;67(5):989-1000
78. Svehlíková V, Wang S, Jakubíková J, Williamson G, Mithen R, Bao YP. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis 2004;25(9):1629-37
79. Bock KW, Eckle T, Ouzzine M, Fournel-Gigleux S. Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resitance protein 2) in Caco-2 cells. Biochem Pharmacol 2000;59(5):467-70
80. Sun XY, Plouzek CA, Henry JP, Wang TTY, Phang JM. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 1998;58(11):2379-84
81. Williams JA, Ring BJ, Cantrell VE, et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 2002;30(11):1266-73
82. D'Andrea V, Pérez LM, Sánchez Pozzi EJ. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin-glucuronide. Life Sci 2005;77(6):683-92
83. Van Der Logt EMJ, Roelofs HMJ, Nagengast FM, Peters WHM. Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occuring dietary anticarcinogens. Carcinogenesis 2003;24(10):1651-6
84. Brouard C, Siess MH, Vernevaut MF, Suschetet M. Comparison of the effects of feeding quercetin or flavone on hepatic and intestinal drug-metabolizing enzymes of the rat. Food Chem Toxicol 1988;26(2):99-103
85. Siess MH, Guillermic M, Le Bon AM, Suschetet M. Induction of monooxygenase and transferase activities in rat by dietary administration of flavonoids. Xenobiotica 1989;19(12):1379-86
86. Appelt LC, Reicks MM. Soy induces Phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. J Nutr 1999;129(10):1820-6
87. Walle T, Eaton EA, Walle UK. Quercetin, a potent and specific inhibitor of the human P-form phenolsulfotransferase. Biochem Pharmacol 1995;50(5):731-4
88. De Santi C, Pietrabissa A, Mosca F, Rane A, Pacifici GM. Inhibition of phenol sulfotransferase (SULT1A1) by quercetin in human adult and foetal livers. Xenobiotica 2002;32(5):363-8
89. Marchetti F, De Santi C, Vietri M, et al. Differential inhibition of human liver and duodenum sulphotransferase activities by quercetin, a flavonoid present in vegetables, fruit and wine. Xenobiotica 2001;31(12):841-7
90. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, Walle T. Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Drug Metab Dispos 1996;24(2):232-7
91. Vietri M, Vaglini F, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulfation of R(-)-apomorphine in the human liver and duodenum, and its inhibition by mefenamic acid, salicylic acid and quercetin. Xenobiotica 2002;32(7):587-94
92. Harris RM, Wood DM, Bottomley L, et al. Phytoestrogens are potent inhibitors of estrogen sulfation, implications for breast cancer risk and treatment. J Clin Endocrinol Metab 2004;89(4):1779-87
93. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 2000;30(6):609-17
94. Carbonaro M, Grant G, Pusztai A. Evaluation of polyphenol bioavailability in rat small intestine. Eur J Nutr 2001;40(2):84-90
95. Otake Y, Nolan AL, Walle UK, Walle T. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol 2000;73(5):265-70
96. Tamura H, Matsui M. Inhibitory effects of green tea and grape juice on the phenol sulfotransferase activity of mouse intestines and human colon carcinoma cell line, Caco-2. Biol Pharm Bull 2000;23(6):695-9
97. Isozaki T, Tamura H. Epigallocatechin gallate (EGCG) inhibits the sulfation of 1-naphtol in a human colon carcinoma cell line, Caco-2. Biol Pharm Bull 2001;24(9):1076-8
98. Coughtrie MWH, Johnston LE. Interactions between dietary chemicals and human sulfotransferases - molecular mechanisms and clinical significance. Drug Metab Dispos 2001;29(4):522-8
99. Nijhoff WA, Bosboom MA, Smidt MH, Peters WHM. Enhancement of rat hepatic and gastrointestinal glutathione and glutathione S-transferases by α-angelicalactone and flavone. Carcinogenesis 1995;16(3):607-12
100. Tanaka T, Kawabata K, Kakumoto M, et al. Modifying effects of a flavonoid morin on azoxymethane-induced large bowel tumorigenesis in rats. Carcinogenesis 1999;20(8):1477-84
101. Van Zanden JJ, Geraets L, Wortelboer HM, Van Bladeren PJ, Rietjens IMCM, Cnubben NHP. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P 1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 2004;67(8):1607-17
102. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occuring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101(5):461-8
103. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of Phase II enzymes. implications in cancer chemoprevention. Carcinogenesis 1999;20(11):2101-8
104. Kuo HM, Ho HJ, Chao PDL, Chung JG. Quercetin glucuronides inhibited 2-aminofluorene acetylation in human acute myeloid HL-60 leukemia cells. Phytomedicine 2002;9(7):625-31
105. Mizoyama Y, Takaki H, Sugihara N, Furuno K. Inhibitory effect of flavonoids on N-acetylation of 5-aminosalicylic acid in cultured rat hepatocytes. Biol Pharm Bull 2004;27(9):1455-8
106. Kukongviriyapan V, Phromsopha N, Tassaneeyakul W, et al. Inihibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Xenobiotica 2006;36(1):15-28
107. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters Life Sci 2006;78 (18):2116-30
108. Brand W, Schutte ME, Williamson G, et al. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 2006;60(9):508-19
109. Leslie EM, Mao QC, Oleschuk CJ, Deeley RG, Cole SPC. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 2001;59(5):1171-80
110. Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003;92(2):250-7
111. Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004;64(12):4346-52
112. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005;70(4):627-39
113. Van Zanden JJ, Wortelboer HM, Bijlsma S, et al. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 2005;69(4):699-708
114. Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 2007;60(6):789-97
115. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65(5):1208-16
116. Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004;21(7):1263-73
117. Mertens-Talcott SU, De Castro WV, Manthey JA, Derendorf H, Butterweck V. Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food Chem 2007;55(7):2563-8
118. Ohtani H, Ikegawa T, Honda Y, et al. Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharm Res 2007;24(10):1936-43
119. Van Zanden JJ, Van Der Woude H, Vaessen J, et al. The effect of quercetin Phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem Pharmacol 2007;74(2):345-51
120. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71(1):11-20
121. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007;81(4):495-502
122. Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 2005;33(11):1666-72
123. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2006;34(4):577-82
124. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33(4):518-23
125. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur J Pharm Sci 2005;25(2-3):263-71
126. Chen J, Lin H, Hu M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 2005;55(2):159-69
127. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81 (Suppl):S230-S242
128. Ramos S, Sultatos L. Flavonoid-induced alterations in cytochrome P450-dependent biotransformation of the organophosphorus insecticide parathion in the mouse, Toxicology 1998;131(2-3):155-67
129. Saarinen N, Joshi SC, Ahotupa M, Li X, Ämmälä J, Santti R. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. J Steroid Biochem Mol Biol 2001;78(3):231-9
130. Zhang S, Wang X, Sagawa K, Morris ME. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or MDR1A/1B (-/-) mice. Drug Metab Dispos 2005;33(3):341-8
131. Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangeretin juice on midazolam hydroxylation. Clin Pharmacol Ther 2000;67(4):382-90
132. Bonzo JA, Bélanger A, Tukey RH. The role of chrysin and the Ah receptor in induction of the human UGT 1A1 gene in vitro and in transgenic UGT1 mice. Hepatology 2007;45(2):349-60
133. Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 2007;55(18):7620-5
134. Peng WX, Li HD, Zhou HH. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol 2003;59(3):237-41
135. Rajnarayana K, Reddy MS, Krishna DR. Diosmin pretreatment affects bioavailability of metronidazole. Eur J Clin Pharmacol 2003;58(12):803-7
136. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004;54(2):109-13
137. Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm 2004;61(22):2406-9
138. Cermak R, Landgraf S, Wolffram S. The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J Nutr 2003;133(9):2802-7
139. Mullen W, Edwards CA, Crozier A. Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr 2006;96(1):107-16
140. Silberberg M, Gil-Izquierdo A, Combaret L, Rémésy C, Scalbert A, Morand C. Flavanone metabolism in healthy and tumor-bearing rats. Biomed Pharmacother 2006;60(9):529-35
141. Hamada M, Satsu H, Natsume Y, et al. TCDD-induced CYP1A1 expression, an index of dioxin toxicity, is suppressed by flavonoids permeating the human intestinal Caco-2 cell monolayers. J Agric Food Chem 2006;54(23):8891-8
142. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2. Dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006;44(5):636-50
143. Okamoto T. Safety of quercetin for clinical application. Int J Mol Med 2005;16(2):275-8
144. MacGregor JT, Collins JM, Sugiyama Y, et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001;59(1):17-36
145. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann Rev Pharmacol Toxicol 1998;38:461-99
146. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Predictions of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50(3):387-411
147. Marathe PH, Rodrigues AD. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Curr Drug Metab 2006;7(7):687-704
148. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007;3(1):81-92
149. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 2006;3(1):62-9
150. Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol 1995;48(5):367-71
151. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31(5):533-9
152. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000;30(9):857-66
153. Ghazali RA, Waring RH. The effects of flavonoids on human phenolsulphotransferases: potential in drug metabolism and chemoprevention. Life Sci 1999;65(16):1625-32